Progyny AI Stock Analysis
Want to see PGNY full AI Analyst Report?
Progyny (PGNY) AI Stock Analysis
Progyny
(NASDAQ:PGNY)
The score is driven primarily by strong financial quality (low leverage and solid free cash flow) and a very positive earnings call with raised guidance, record client/lives additions, and ongoing buybacks. Technicals are supportive with price above major moving averages, though momentum is somewhat elevated. Valuation is the main limiter given the ~26 P/E and no dividend yield support.
Progyny Key Performance Indicators (KPIs)
Fertility and Family Building ClientsCounts employer groups and other clients that buy Progyny’s fertility and family-building benefits, revealing sales momentum, market penetration, contract scale, and concentration risk from large customers.
Client counts have grown steadily and accelerated year-over-year, with clear inflection points tied to large renewals, enterprise wins and brownfield conversions; management says retention risk for 2027 is largely removed and early sales are pacing ahead, supporting the 1M+ lives target. Near-term summer seasonality and a comparability hit from a transition client temper sequential visibility, but strong cash conversion, margin expansion and active buybacks suggest these membership gains should convert into durable revenue and free cash flow tailwinds.
Progyny (PGNY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.70B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.09M
- Price to Earnings (P/E)
- 31.8
- Beta (1Y)
- 0.42
- Revenue Growth
- 5.52%
- EPS Growth
- 74.23%
- Country
- US
- Employees
- 846
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Plans
Progyny Business Overview & Revenue Model
Company Description
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized b...
How the Company Makes Money
Progyny makes money primarily by selling fertility and family-building benefits solutions to employers (especially self-insured employers) on a contractual basis and administering those benefits for employer clients. Key revenue streams include: (1)...
Progyny Earnings Call Summary
The call was strongly positive, with record new-client and covered-life additions, near 100% retention, healthy utilization, improved gross margins, strong cash generation, significant share repurchases and raised full-year guidance. The main challenges were a modest year-over-year decline in adjusted EBITDA margin, temporary third-quarter seasonality, elevated medical cost inflation and the currently immaterial contribution from Progyny Select.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, Progyny is now projecting revenue of between $1.365 billion to $1.385 billion, reflecting growth of 5.9% to 7.5%; excluding the $48.5 million in revenue from the client who is under a transition of care agreement over the first half of 2025, full year revenue growth is projected to be 10.1% to 11.7%. Adjusted EBITDA is expected to be $235 million to $240 million, net income $107 million to $110.6 million, earnings per diluted share $1.30 and $1.35, and adjusted EPS $2.09 and $2.13 on the basis of approximately 82 million fully diluted shares. For the fourth quarter, revenue is expected to be $344.7 million to $364.7 million, for growth of 8.3% to 14.6%, adjusted EBITDA between $57.9 million to $62.9 million, net income between $28.5 million to $32.1 million, earnings per diluted share $0.36 and $0.41, and adjusted EPS $0.53 and $0.58 on the basis of 79 million fully diluted shares; at the midpoint of ranges for both the quarter and the year, the company expects to maintain a consistent adjusted EBITDA margin. The majority of the over 85 clients and 1.3 million lives added in the most recent selling season are expected to go live in the first quarter of 2027, with a meaningful number of lives, several hundred thousand, give or take, expected to launch midyear; once all the new clients are live in 2027, Progyny anticipates having more than 660 clients, representing 8.3 million covered lives.
Progyny Financial Statement Overview
Summary
Strong overall fundamentals driven by improving profitability and margins (TTM net margin ~6.8% and rising gross margin ~24.9%), very low leverage (debt-to-equity ~0.05), and solid free cash flow generation (TTM FCF ~$219M). Key offsets are historically volatile margins and inconsistent cash conversion (operating cash flow vs. net income fluctuating over time).
Income Statement
78PositiveBalance Sheet
86Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.34B | 1.29B | 1.17B | 1.09B | 786.91M | 500.62M |
| Gross Profit | 332.99M | 304.48M | 253.36M | 238.80M | 167.32M | 112.14M |
| EBITDA | 140.40M | 100.38M | 86.38M | 72.97M | 26.04M | 33.74M |
| Net Income | 91.02M | 58.52M | 54.34M | 62.04M | 30.36M | 65.77M |
Balance Sheet | ||||||
| Total Assets | 675.79M | 742.43M | 607.10M | 756.62M | 542.99M | 358.06M |
| Cash, Cash Equivalents and Short-Term Investments | 195.59M | 310.10M | 227.95M | 371.09M | 189.30M | 119.42M |
| Total Debt | 21.73M | 27.73M | 19.27M | 19.39M | 7.71M | 8.65M |
| Total Liabilities | 261.76M | 226.39M | 185.04M | 203.19M | 166.02M | 106.24M |
| Stockholders Equity | 414.03M | 516.04M | 422.06M | 553.43M | 376.97M | 251.82M |
Cash Flow | ||||||
| Free Cash Flow | 219.24M | 191.78M | 173.70M | 185.17M | 77.15M | 23.91M |
| Operating Cash Flow | 253.13M | 210.19M | 179.10M | 188.81M | 80.39M | 26.04M |
| Investing Cash Flow | 199.98M | -159.01M | 195.79M | -200.53M | -43.87M | 8.77M |
| Financing Cash Flow | -454.78M | -99.36M | -309.88M | -11.07M | -7.86M | -13.70M |
Progyny Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGNY, the sentiment is Positive. The current price of 36.71 is above the 20-day moving average (MA) of 32.06, above the 50-day MA of 28.90, and above the 200-day MA of 24.95, indicating a bullish trend. The MACD of 2.52 indicates Negative momentum. The RSI at 77.81 is Negative, neither overbought nor oversold. The STOCH value of 92.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PGNY.
Progyny Risk Analysis
Progyny disclosed 57 risk factors in its most recent earnings report. Progyny reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksProgyny Peers Comparison
Overall Rating
PGNY79Outperform
ELV76Outperform
CI75Outperform
CVS71Outperform
UNH62Neutral
HUM58Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | $2.70B | 31.84 | 19.98% | ― | 5.52% | 74.23% | |
| 76Outperform | $93.75B | 18.45 | 11.59% | 1.58% | 3.60% | -4.06% | |
| 75Outperform | $77.49B | 12.92 | 14.10% | 2.11% | 6.79% | -0.38% | |
| 71Outperform | $109.79B | 9.88 | 14.13% | 3.10% | 6.77% | 2114.64% | |
| 62Neutral | $349.16B | 22.14 | 16.35% | 2.33% | 3.33% | -8.75% | |
| 58Neutral | $53.25B | 42.48 | 6.70% | 0.80% | 22.02% | -3.07% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PGNY | Progyny, Inc. | 36.71 | 11.88 | 47.85% | |
| CI | Cigna | 294.06 | 30.44 | 11.54% | |
| CVS | CVS Health Corp | 85.81 | 12.04 | 16.31% | |
| HUM | Humana | 443.34 | 222.93 | 101.14% | |
| UNH | Unitedhealth Group Inc. | 389.68 | 86.22 | 28.41% | |
| ELV | Elevance Health, Inc. | 433.93 | 126.06 | 40.95% |
Progyny Corporate Events
Progyny Reports Record Third-Quarter Financial Results and Growth
PositiveProgyny, Inc. is a global women’s health and family-building company offering fertility and pharmacy benefit services, along with pregnancy, parenting and menopause support for employer-sponsored covered lives. On November 4, 2026, the company report...
Progyny Posts Record Q2 Results, Expands Client Base
PositiveOn August 6, 2026, Progyny reported record second‑quarter 2026 results, with revenue rising 5.3% year on year to $350.5 million and gross profit climbing 13% to $89.3 million, despite the loss of a large client that had contributed $17.2 million in t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
